Long-Term Effects of Multiple Intravitreal Antivascular Endothelial Growth Factor Injections on Intraocular Pressure

详细信息    查看全文

• 作者：Yoon Jeon KimAuthor Vitae ; Kyung Rim Sung ; Kyoung Sub Lee ; Soo Geun Joe ; Joo Yong Lee ; June-Gone Kim ; Young Hee Yoon ; ^{yhyoon@amc.seoul.kr" class="auth_mail}
• 刊名：American Journal of Ophthalmology
• 出版年：June 2014
• 年：2014
• 卷：157
• 期：6
• 页码：1266-1271.e1
• 全文大小：408 K

文摘

To evaluate long-term effects of multiple intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP) in eyes with neovascular age-related macular degeneration (AMD) or retinal vein occlusion (RVO).

Design

Retrospective cohort study.

Methods

This study enrolled patients who underwent multiple (more than 3) intravitreal anti-VEGF injections and who were followed for more than 12 months after their last injection. IOP elevation was defined as an increase of 5 mm Hg over the baseline measurement on 2 consecutive visits. The frequency of IOP elevation was determined. A hazard ratio of each putative risk factor for IOP elevation was calculated using the Cox proportional hazard model for all participants, incorporating underlying disease as a covariate, as well as for each cohort.

Results

Included in the analysis were 629 eyes with neovascular AMD and 95 eyes with RVO. Twenty eyes with neovascular AMD (3.0%) and 7 eyes with RVO (7.4%) experienced IOP elevation after multiple anti-VEGF injections, with an overall incidence of 3.7%. In the Cox proportional hazard analysis of total participants, a diagnosis of RVO (3.424, P = 0.005), a history of glaucoma (8.441, P = 0.001), and low baseline IOP (0.865, P = 0.040) were all significant risk factors for IOP elevation after multiple anti-VEGF injections.

Conclusion

A history of multiple intravitreal anti-VEGF injections was not a significant risk factor for IOP elevation in our study. IOP elevation was more common in eyes with RVO than with AMD after anti-VEGF injection.